Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032747 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 338
- Enrollment target
NCT00032747: Completed Phase 2 study, sponsored by Sanofi.
NCT00032747 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 338 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (154% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032747, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 338 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group forced up-titration study. Randomization will be stratified according to the patient's baseline serum sodium concentration (137-144 and \<137 mmol/L). The dose of study drug will be increased to the next level on Day 15, and the total duration of the double-blind treatment period is 120 days.
Interventions
- DRUG Vasopressin V2 Receptor Antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2001-08 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
What the finished NCT00032747 record still lists
NCT00032747 is an interventional study that assigns participants to a tested intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (154% higher).
The record links to 0 conditions, and to 1 intervention - of which Vasopressin V2 Receptor Antagonist is the first listed.
NCT00032747 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00032747 about?
NCT00032747 is a clinical study titled "Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).". This is a randomized, double-blind, placebo-controlled, parallel-group forced up-titration study. Randomization will be stratified according to the patient's baseline serum sodium concentration (137-144 and \<137 mmol/L). The dose of study drug will be increased to the next level on Day 15, and the ...
What is the current status of trial NCT00032747?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2001-08. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00032747?
The interventions under investigation include: Vasopressin V2 Receptor Antagonist (DRUG).
Who is sponsoring clinical trial NCT00032747?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00032747's enrollment target sits among peer trials
338 140th of 2000 higher than 1,860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia